We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00135434
First Posted: August 26, 2005
Last Update Posted: April 8, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bristol-Myers Squibb
August 25, 2005
August 26, 2005
April 8, 2011
September 2004
June 2005   (Final data collection date for primary outcome measure)
Insulin sensitivity by euglycemic hyperinsulinemic clamp method
Not Provided
Complete list of historical versions of study NCT00135434 on ClinicalTrials.gov Archive Site
  • Insulin sensitivity by oral glucose tolerance
  • Lipids and lipoproteins
Not Provided
Not Provided
Not Provided
 
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV Infections
Drug: Atazanavir/Ritonavir/Lopinavir/ritonavir
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
June 2005
June 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00135434
AI424-130
Not Provided
Not Provided
Not Provided
Study Director, Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP